0 Views
0 Likes
0 Shares
0 Comments
Read article ↗

StayCurrentMD

View profile →

Article

Outcomes of Allogeneic Umbilical Cord Mesenchymal Stem Cell Infusion for Liver Cirrhosis Due to Biliary Atresia After Kasai Operation

Published: Reading: 1 min

Topic overview

This study evaluates allogeneic umbilical cord mesenchymal stem cell infusion as an adjunct therapy for liver cirrhosis in biliary atresia patients post-Kasai operation. The research addresses the limited long-term survival after Kasai surgery by exploring regenerative cell-based approaches to improve hepatic outcomes in this pediatric population.

Key takeaways

  • Kasai surgery for biliary atresia has limited long-term survival despite initial success in restoring bile flow.
  • Allogeneic umbilical cord mesenchymal stem cells (UC-MSCs) are being investigated as adjunctive therapy post-Kasai.
  • Cell therapy may offer a novel approach to manage progressive liver cirrhosis in biliary atresia patients.
  • UC-MSC infusion safety and efficacy data could inform future regenerative strategies for pediatric liver disease.

Keywords

Biliary Atresia Kasai Portoenterostomy Mesenchymal Stem Cells Liver Cirrhosis Pediatric Hepatology Regenerative Medicine Umbilical Cord Stem Cells

Hashtags

#BiliaryAtresia #StemCellTherapy #PediatricHepatology #RegenerativeMedicine

Full article text

Full article text not available for this entry
How to cite: GlobalCastMD. Outcomes of Allogeneic Umbilical Cord Mesenchymal Stem Cell Infusion for Liver Cirrhosis Due to Biliary Atresia After Kasai Operation. GlobalCastMD Medical Library. 2025-09-02. https://library.globalcastmd.com/article/10934

Comments

Loading comments...